West Pharmaceutical Services Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" West Pharmaceutical Services stock.
View analyst ratings for West Pharmaceutical Services or view top-rated stocks.

Wall Street analysts have given West Pharmaceutical Services a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but West Pharmaceutical Services wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

West Pharmaceutical Services saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 967,000 shares, a decline of 13.7% from the June 30th total of 1,120,000 shares. Based on an average trading volume of 379,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.3% of the shares of the stock are sold short.
View West Pharmaceutical Services' Short Interest.

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for West Pharmaceutical Services.

West Pharmaceutical Services, Inc. (NYSE:WST) issued its quarterly earnings results on Thursday, July, 29th. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.74 by $0.72. West Pharmaceutical Services had a trailing twelve-month return on equity of 29.50% and a net margin of 20.58%.
View West Pharmaceutical Services' earnings history.

West Pharmaceutical Services' stock was trading at $147.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, WST stock has increased by 178.5% and is now trading at $411.73.
View which stocks have been most impacted by COVID-19.

West Pharmaceutical Services announced a quarterly dividend on Wednesday, May 5th. Shareholders of record on Wednesday, July 21st will be paid a dividend of $0.17 per share on Wednesday, August 4th. This represents a $0.68 annualized dividend and a yield of 0.17%. The ex-dividend date is Tuesday, July 20th.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services pays an annual dividend of $0.68 per share and currently has a dividend yield of 0.17%. West Pharmaceutical Services has been increasing its dividend for 25 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of West Pharmaceutical Services is 14.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 8.77% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services issued an update on its FY 2021 earnings guidance on Thursday, July, 29th. The company provided EPS guidance of $8.050-$8.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.140. The company issued revenue guidance of $2.76 billion-$2.79 billion, compared to the consensus revenue estimate of $2.68 billion.

2 brokers have issued 1-year price objectives for West Pharmaceutical Services' stock. Their forecasts range from $300.00 to $475.00. On average, they anticipate West Pharmaceutical Services' stock price to reach $387.50 in the next twelve months. This suggests that the stock has a possible downside of 5.9%.
View analysts' price targets for West Pharmaceutical Services or view top-rated stocks among Wall Street analysts.

107 employees have rated West Pharmaceutical Services CEO Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among West Pharmaceutical Services' employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Some companies that are related to West Pharmaceutical Services include Align Technology (ALGN), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), STAAR Surgical (STAA), Neogen (NEOG), ICU Medical (ICUI), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Meridian Bioscience (VIVO), Cerus (CERS), OraSure Technologies (OSUR), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all of WST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), The Walt Disney (DIS), The Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by a variety of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.39%), Intermede Investment Partners Ltd (0.30%), Alliancebernstein L.P. (0.14%), Conestoga Capital Advisors LLC (0.14%), State of Alaska Department of Revenue (0.05%) and Whittier Trust Co. (0.03%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Oregon Public Employees Retirement Fund, Intermede Investment Partners Ltd, Alliancebernstein L.P., State of Alaska Department of Revenue, Sound Financial Strategies Group LLC, Security Asset Management, and Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold West Pharmaceutical Services company stock in the last year include George Lloyd Miller, and Silji Abraham.
View insider buying and selling activity for West Pharmaceutical Services or view top insider-selling stocks.

WST stock was bought by a variety of institutional investors in the last quarter, including Bright Rock Capital Management LLC, CBOE Vest Financial LLC, Conestoga Capital Advisors LLC, Arkadios Wealth Advisors, Marshall Financial Group LLC, Whittier Trust Co., IFM Investors Pty Ltd, and Heartland Bank & Trust Co.
View insider buying and selling activity for West Pharmaceutical Services or or view top insider-buying stocks.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $411.73.

West Pharmaceutical Services has a market capitalization of $30.39 billion and generates $2.15 billion in revenue each year. The medical instruments supplier earns $346.20 million in net income (profit) each year or $4.76 on an earnings per share basis.

West Pharmaceutical Services employs 9,200 workers across the globe.

The following companies are subsidiares of West Pharmaceutical Services: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., TGPR Holdings Limited, Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), The Tech Group Inc., W.P.S.F. Limited, WD SG Pte. Ltd., West Analytical Services LLC, West Contract Manufacturing LLC, West Pharma. Services IL Ltd., West Pharmaceutical Packaging (China) Company Ltd., West Pharmaceutical Packaging India Private Limited, West Pharmaceutical Products Ireland Ltd., West Pharmaceutical Services AZ Inc., West Pharmaceutical Services Argentina S.A., West Pharmaceutical Services Asia Ltd., West Pharmaceutical Services Australia Pty. Ltd., West Pharmaceutical Services Beograd d.o.o., West Pharmaceutical Services Brasil Ltda., West Pharmaceutical Services Colombia S.A.S., West Pharmaceutical Services Cornwall Limited, West Pharmaceutical Services Danmark A/S, West Pharmaceutical Services Delaware Acquisition Inc., West Pharmaceutical Services Deutschland GmbH Co KG, West Pharmaceutical Services France S.A.S., West Pharmaceutical Services Group Limited, West Pharmaceutical Services Hispania S.A., West Pharmaceutical Services Holding Danmark ApS, West Pharmaceutical Services Holding France SAS, West Pharmaceutical Services Holding GmbH, West Pharmaceutical Services Holding II GmbH, West Pharmaceutical Services Holding Ireland North Ltd., West Pharmaceutical Services Holding Ireland South Ltd., West Pharmaceutical Services Holding Japan GK, West Pharmaceutical Services Holdings Ltd., West Pharmaceutical Services Italia S.r.L., West Pharmaceutical Services Korea Ltd., West Pharmaceutical Services Lakewood Inc., West Pharmaceutical Services Normandie SAS, West Pharmaceutical Services Shanghai Medical Rubber Products Co. Ltd., West Pharmaceutical Services Singapore (Holding) Pte. Limited, West Pharmaceutical Services Singapore Pte. Ltd., West Pharmaceutical Services Switzerland GmbH, West Pharmaceutical Services Venezuela C.A., West Pharmaceutical Services Verwaltungs GmbH, West Pharmaceutical Services of Delaware Inc., and West Pharmaceutical Services of Florida Inc..

West Pharmaceutical Services was founded in 1923.

The official website for West Pharmaceutical Services is www.westpharma.com.

West Pharmaceutical Services is headquartered at 530 HERMAN O. WEST DRIVE, EXTON PA, 19341.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]